All posts by BTS Research

FDA Changes EUA So Olumiant Can Stand Alone in Treating COVID-19

By | Drug Industry Daily | No Comments

The FDA has revised its Emergency Use Authorization (EUA) for Eli Lilly’s and Incyte’s COVID-19 treatment Olumiant (baricitinib) to authorize giving the drug alone for the treatment of COVID-19 in hospitalized adults and pediatric patients two years or older requiring supplemental oxygen, noninvasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation.
Source: Drug Industry Daily